NNVC Nanoviricides Inc
Price (delayed)
$1.5
Market cap
$23.46M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.72
Enterprise value
$19.5M
NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped
Highlights
The EPS has grown by 11% YoY and by 5% from the previous quarter
NNVC's quick ratio is up by 41% since the previous quarter but it is down by 39% year-on-year
The equity has declined by 17% year-on-year but it has grown by 2.8% since the previous quarter
Key stats
What are the main financial stats of NNVC
Market
Valuations
Earnings
Shares outstanding
15.64M
Market cap
$23.46M
Enterprise value
$19.5M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.07
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$9.53M
Net income
-$9.36M
EBIT
-$9.36M
EBITDA
-$8.59M
Free cash flow
-$8.4M
Per share
Balance sheet
Liquidity
EPS
-$0.72
EPS diluted
-$0.72
Free cash flow per share
-$0.58
Book value per share
$0.72
Revenue per share
$0
TBVPS
$0.77
Total assets
$11.57M
Total liabilities
$1.18M
Debt
$0
Equity
$10.39M
Working capital
$2.89M
Debt to equity
0
Current ratio
3.44
Quick ratio
3.34
Net debt/EBITDA
0.46
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-78.7%
Return on equity
-87.9%
Return on invested capital
-147.6%
Return on capital employed
-90.2%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NNVC stock price
How has the Nanoviricides stock price performed over time
Intraday
3.45%
1 week
11.11%
1 month
33.93%
1 year
20.97%
YTD
4.9%
QTD
4.9%
Financial performance
How have Nanoviricides's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$9.53M
Net income
-$9.36M
Gross margin
N/A
Net margin
N/A
Growth
What is Nanoviricides's growth rate over time
Valuation
What is Nanoviricides stock price valuation
P/E
N/A
P/B
2.07
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 11% YoY and by 5% from the previous quarter
The stock's price to book (P/B) is 38% more than its 5-year quarterly average of 1.5 and 15% more than its last 4 quarters average of 1.8
The equity has declined by 17% year-on-year but it has grown by 2.8% since the previous quarter
Efficiency
How efficient is Nanoviricides business performance
Nanoviricides's return on equity has decreased by 37% YoY and by 3.9% QoQ
NNVC's return on assets is down by 35% year-on-year and by 2.9% since the previous quarter
Nanoviricides's return on invested capital has decreased by 25% YoY and by 2.2% QoQ
Dividends
What is NNVC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NNVC.
Financial health
How did Nanoviricides financials performed over time
NNVC's quick ratio is up by 41% since the previous quarter but it is down by 39% year-on-year
The current ratio has increased by 39% QoQ but it has decreased by 38% YoY
NNVC's debt is 100% lower than its equity
The equity has declined by 17% year-on-year but it has grown by 2.8% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.